

ASX ANNOUNCEMENT

Appendix 4C – Quarterly Cash Flow Report

Highlights for the quarter ended 31st March 2018

- **Share options exercise raises \$1,039k January 2018**
- **Cash balance as of 31st March, \$1,133k**
- **\$1,370k cash received if all options exercised 31st May 2018**
- **\$939k tax incentive paid April 2018**
- **Revolutionary PeriCoach[®] technique scoring demonstrates game changing success.**

30th April 2018: Analytica Ltd (ASX: ALT), manufacturer of the PeriCoach[®] system and the AutoStart[®] and AutoFlush infusion system technologies, has today released its Appendix 4C - Quarterly Cashflow report for period ending 31st March 2018.

Receipts from sales of PeriCoach in Analytica's key markets of Australia, the UK and the US totalled \$11k, with extremely limited commercial activity occurring. The marketing activity is focused on recruitment for data collection and feature development. Research & development expenditure was \$282k, dominated by expenditure on the PeriCoach "big data" project, the largest and most comprehensive pelvic floor muscle exercise database and analysis platform in the world. \$272k was incurred on staff costs. Administration costs of \$127k.

It is anticipated that with increased travel overseas this coming quarter to support the sale of company by merchant banker Navigant, expenditure will be higher this quarter.

During the quarter, the company received \$1,039k of capital.

The Board and management appreciate the confidence of our major shareholders for supporting the exercise of these options. These funds are being deployed to continue the development of the PeriCoach System and advance negotiations with potential partners.

On the 31st of May the options issued on 17th October 2017 at \$0.005 expire. If fully subscribed this would contribute \$1,370k in additional capital.

Analytica received in April 2018, \$939k tax refund for research and development tax incentive for this last financial year. This is a much appreciated incentive by the Australian government to encourage the ground breaking research and development Analytica has been undertaking.

The company also has access to a \$400k loan facility. Directors are monitoring capital requirements to ensure the company has adequate cash to continue development and undertake partnering negotiations of the PeriCoach and the AutoFlush and AutoStart burette technologies. The Company continues to have the financial support of its major shareholders.

Research and development continue this quarter with further development of data analysis tools. Continued investment in real world data-gathering tools to increase the sophistication of analysis of user behaviour and



pelvic health information is the cornerstone of company strategy.

Analytica is working closely with Navigant Capital Advisors LLC, (appointment, announced 6th November) with the process for the sale of the PeriCoach, AutoStart and AutoFlush.

As outlined in the Chairman's address to the Annual General Meeting in November 2017, Analytica is achieving its goals set out at the Annual General meeting 2016 of being deal-ready. This quarter demonstrates further strong progress to the Company strategy; build a product that is best in class, gather evidence that the product performance is exceptional, and actively pursue partnering opportunities.

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:



About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale from pericoach.com in Australia and New Zealand, UK and Ireland.



Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Analytica Ltd

ABN

12 006 464 866

Quarter ended ("current quarter")

March 2018

| Consolidated statement of cash flows | Current quarter \$A'000 | Year to date (9 months) \$A'000 |
|---|------------------------------------|--|
| 1. Cash flows from operating activities | | |
| 1.1 Receipts from customers | 11 | 52 |
| 1.2 Payments for | | |
| (a) research and development | (282) | (996) |
| (b) product manufacturing and operating costs | 8 | 10 |
| (c) advertising and marketing | (26) | (96) |
| (d) leased assets | | |
| (e) staff costs | (272) | (854) |
| (f) administration and corporate costs | (127) | (474) |
| 1.3 Dividends received (see note 3) | | |
| 1.4 Interest received | 3 | 8 |
| 1.5 Interest and other costs of finance paid | | |
| 1.6 Income taxes paid | | |
| 1.7 Government grants and tax incentives | | |
| 1.8 Other (provide details if material) | 6 | 6 |
| 1.9 Net cash from / (used in) operating activities | (679) | (2,344) |

| | | |
|--|--|-----|
| 2. Cash flows from investing activities | | |
| 2.1 Payments to acquire: | | |
| (a) property, plant and equipment | | (3) |
| (b) businesses (see item 10) | | |
| (c) investments | | |

| Consolidated statement of cash flows | Current quarter \$A'000 | Year to date (9 months) \$A'000 |
|---|----------------------------|---------------------------------------|
| (d) intellectual property | | |
| (e) other non-current assets | | |
| 2.2 Proceeds from disposal of: | | |
| (a) property, plant and equipment | | |
| (b) businesses (see item 10) | | |
| (c) investments | | |
| (d) intellectual property | | |
| (e) other non-current assets | | |
| 2.3 Cash flows from loans to other entities | | |
| 2.4 Dividends received (see note 3) | | |
| 2.5 Other (provide details if material) | | |
| 2.6 Net cash from / (used in) investing activities | | (3) |

| | | |
|---|--------------|--------------|
| 3. Cash flows from financing activities | | |
| 3.1 Proceeds from issues of shares | 1,039 | 2,408 |
| 3.2 Proceeds from issue of convertible notes | | |
| 3.3 Proceeds from exercise of share options | | |
| 3.4 Transaction costs related to issues of shares, convertible notes or options | (26) | (140) |
| 3.5 Proceeds from borrowings | | |
| 3.6 Repayment of borrowings | | |
| 3.7 Transaction costs related to loans and borrowings | | |
| 3.8 Dividends paid | | |
| 3.9 Other (provide details if material) | | |
| 3.10 Net cash from / (used in) financing activities | 1,013 | 2,268 |

| | | |
|---|-------|---------|
| 4. Net increase / (decrease) in cash and cash equivalents for the period | | |
| 4.1 Cash and cash equivalents at beginning of quarter/year to date | 799 | 1,212 |
| 4.2 Net cash from / (used in) operating activities (item 1.9 above) | (679) | (2,344) |
| 4.3 Net cash from / (used in) investing activities (item 2.6 above) | | (3) |
| 4.4 Net cash from / (used in) financing activities (item 3.10 above) | 1,013 | 2,268 |

| Consolidated statement of cash flows | | Current quarter \$A'000 | Year to date (9 months) \$A'000 |
|---|--|------------------------------------|--|
| 4.5 | Effect of movement in exchange rates on cash held | | |
| 4.6 | Cash and cash equivalents at end of quarter | 1,133 | 1,133 |

| 5. | Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts | Current quarter \$A'000 | Previous quarter \$A'000 |
|------------|---|------------------------------------|-------------------------------------|
| 5.1 | Bank balances | 1,133 | 799 |
| 5.2 | Call deposits | | |
| 5.3 | Bank overdrafts | | |
| 5.4 | Other (provide details) | | |
| 5.5 | Cash and cash equivalents at end of quarter (should equal item 4.6 above) | 1,133 | 799 |

6. Payments to directors of the entity and their associates

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3

| Current quarter \$A'000 |
|------------------------------------|
| 96 |
| 0 |

- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

| |
|--|
| |
|--|

7. Payments to related entities of the entity and their associates

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3

| Current quarter \$A'000 |
|------------------------------------|
| |
| |

- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

| |
|--|
| |
|--|

| 8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i> | Total facility amount at quarter end \$A'000 | Amount drawn at quarter end \$A'000 |
|--|--|---|
| 8.1 Loan facilities | 400 | 0 |
| 8.2 Credit standby arrangements | | |
| 8.3 Other (please specify) | | |
| 8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well. | | |

| |
|--|
| |
|--|

| 9. Estimated cash outflows for next quarter | \$A'000 |
|--|------------|
| 9.1 Research and development | 280 |
| 9.2 Product manufacturing and operating costs | 20 |
| 9.3 Advertising and marketing | 26 |
| 9.4 Leased assets | |
| 9.5 Staff costs | 290 |
| 9.6 Administration and corporate costs | 180 |
| 9.7 Other (provide details if material) | |
| 9.8 Total estimated cash outflows | 796 |

| 10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above) | Acquisitions | Disposals |
|--|--------------|-----------|
| 10.1 Name of entity | | |
| 10.2 Place of incorporation or registration | | |
| 10.3 Consideration for acquisition or disposal | | |
| 10.4 Total net assets | | |
| 10.5 Nature of business | | |

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here: Date:
(Director)

Print name: R. Mangelsdorf

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.